martin

1 Comment

    • Valuing Sepracor Through Astra-Zeneca's MedImmune Goggles [view article]
      What you fail to realize is SEPR's drugs have no intellectual property protection. Valuing SEPRs assets using 25-35x implies terminal value that SEPR simply does not have. Lunesta has but 5 years of IP life left and Xopenex either 1 or 5. MEDI's assets have another 20 years left to them.

      Sorry, this is apples and oranges.
      Apr 27 09:03 AM
Contribute an Article Become a Seeking Alpha Contributor